Enhancing Capital’s AbbVie ABBV Stock Holding History

Enhancing Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$435K	Hold	2,000	–	–	0.32%	62
2025 Q4	$457K	Hold	2,000	–	–	0.33%	63
2025 Q3	$463K	Hold	2,000	–	–	0.34%	66
2025 Q2	$371K	Hold	2,000	–	–	0.28%	75
2025 Q1	$419K	Hold	2,000	–	–	0.34%	72
2024 Q4	$355K	Buy	+2,000	New	+$368K	0.28%	75
2022 Q3	$278K	Hold	2,000	–	–	0.34%	64
2022 Q2	$306K	Hold	2,000	–	–	0.37%	61
2022 Q1	$324K	Hold	2,000	–	–	0.35%	64
2021 Q4	$271K	Buy	+2,000	New	+$236K	0.29%	69

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Enhancing Capital's ABBV Position: Q1 2026 in Review

Enhancing Capital held its AbbVie (ABBV) position steady in Q1 2026 at 2,000 shares worth $435K. The position accounts for 0.32% of the portfolio, ranked #62.

Enhancing Capital first reported a position in ABBV in Q4 2021 and has held it in 10 quarters since. The position peaked at $463K in Q3 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Enhancing Capital held 2,000 shares of AbbVie worth $435K as of Q1 2026.
Enhancing Capital left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 0.32% of Enhancing Capital's portfolio in Q1 2026, its #62 holding.
Enhancing Capital first reported a position in AbbVie in Q4 2021 and has held it in 10 quarters since.
Enhancing Capital's AbbVie position peaked at $463K in Q3 2025.
4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Enhancing Capital's 13F filing for Q1 2026, filed 8 May 2026.